OptimizeRx Launches EHR-Enabled Specialty Hub Enrollment Form
18 Februar 2020 - 2:31PM
OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital
health solutions for life science companies and payers, has
launched its first health technology solution from OptimizeRx
Innovation Lab, aimed at increasing speed to therapy for patients
by providing timely access to enrollment forms within the provider
workflow, making it easier for patients to enroll in specialty drug
support programs provided by hub services.
Part of the OptimizeRx platform, the new hub-enrollment solution
improves patient access to specialty medications in two ways:
First, it alerts healthcare providers that the chosen drug must be
filled at a specialty pharmacy – at the time that the provider is
writing the script in the electronic health record (EHR). Second,
the solution automatically surfaces the hub-enrollment form in the
EHR, allowing the provider to give it to the patient while in the
office.
Providers are often unaware that they must complete part of the
enrollment form. Lack of awareness and difficulty completing these
forms are often barriers to successfully filling specialty
prescriptions for patients. This point-of-care messaging helps
overcome those barriers by alerting providers within the EHR when
hub-enrollment is required for a drug that they are
prescribing.
The hub-enrollment solution further bridges the gap in
communication by providing pharma companies with a unique
opportunity to communicate these programs to healthcare providers
at the point of prescribing and in their existing workflow, so that
they can better support patients by helping them quickly enroll. It
is the first offering from the newly founded OptimizeRx Innovation
Lab, which allows life science companies to experiment with new
digital communication solutions and quickly test them with
providers. The prescription enrollment feature is available to
participants on the OptimizeRx platform starting this year.
“The OptimizeRx hub-enrollment solution increases patient access
to specialty drugs right at the point of care using technology to
assist providers to easily route specialty scripts correctly to a
hub or specialty pharmacy,” noted Miriam Paramore, OptimizeRx’s
president. “In addition, patient enrollment forms must be completed
before the script is filled. We are excited to enable greater
patient access to therapy. Our goal is to help patients get their
medicine quickly, by removing barriers to access.”
The EHR specialty prescription enrollment capability is just the
first technological advancement from the Innovation Lab that
OptimizeRx is bringing to market in 2020. The Innovation Lab drives
new solutions that will be delivered through the OptimizeRx
Integrated Communications Platform – helping connect providers
and patients with the most appropriate treatment options to help
people realize the best possible health outcomes.
About OptimizeRx
OptimizeRx® (NASDAQ: OPRX), a digital health company, connects
pharmaceutical companies to patients and providers, offering
greater affordability, adherence and brand awareness at the
point-of-care. As the nation’s largest digital platform connecting
life sciences to the point-of-care, OptimizeRx provides a direct
channel for pharma companies, payers, medtech, and medical
associations to communicate with healthcare providers right within
their workflow and directly to patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half of the
ambulatory patient market with access to these benefits through
leading EHR platforms like Allscripts, Amazing Charts and Quest,
and directly via its mobile communications digital care management
platform.
For more information, follow the company on
Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934,
as amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition, and other material risks.
OptimizeRx Contact
Doug Baker, CFO Tel (248) 651-6568
x807 dbaker@optimizerx.com
Media Relations Contact
Maira Alejandra, Media Relations Manager Tel (248) 651-6568 x807
malejandra@optimizerx.com
Investor Relations Contact
Ron Both, CMA Tel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024